Described herein are compositions, methods, and techniques to generate a cancer signature and uses thereof. The cancer signature can be used to determine a cancer progression risk of a subject based upon expression levels of genes of a progression gene signature in a sample. The methods can be used to predict a prognosis, to select an appropriate treatment regimen, to identify or screen for an agent effective against a cancer, or a combination thereof. Computer implemented methods and systems that implement those methods are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Described herein are compositions, methods, and techniques to generate a cancer signature and uses thereof. The cancer signature can be used to determine a cancer progression risk of a subject based upon expression levels of genes of a progression gene signature in a sample. The methods can be used to predict a prognosis, to select an appropriate treatment regimen, to identify or screen for an agent effective against a cancer, or a combination thereof. Computer implemented methods and systems that implement those methods are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention provides methods for selecting a cancer patient who is AHR nuclear positive, and methods for treating cancer comprising selecting a cancer patient who is AHR nuclear positive, and administering to the patient an AHR inhibitor.

Provided are methods and compositions for identifying inhibitors of an interaction between the oncogenic transcription factor MYC and its cofactor TRRAP. The methods involve both cell-based and in vitro approaches for probing an interaction between MYC and TRRAP and for identifying inhibitors of a MYC-TRRAP interaction. Also provided are compounds for use as inhibitors of an interaction between MYC and TRRAP, and methods for developing a cancer therapeutic from such compounds, including methods for derivatizing such inhibitors and for testing the inhibitors and derivatized inhibitors for an ability to treat cancer in a subject. The methods, compounds, and compositions provided herein can provide various advantages, such as a means to target the oncogenic transcription factor MYC in cancer.

The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Provided are a composition for diagnosing breast cancer and a method of diagnosing breast cancer using the same. Breast cancer may be diagnosed using blood in a simple manner.

Provided are a composition for diagnosing breast cancer and a method of diagnosing breast cancer using the same. Breast cancer may be diagnosed using blood in a simple manner.

This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.

This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.

This invention relates to a novel approach for the identification and stratification of subtypes of cancer, particularly subtypes of cancer characterized by an increased expression of BCAT1, particularly Acute Myeloid Leukemia (AML). The invention furthermore relates to a novel approach with respect to the treatment of cancer, particularly subtypes of cancer characterized by an increased expression of BCAT1, particularly Acute Myeloid Leukemia (AML).